1. Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite
- Author
-
Kenji Maeda, Shiro Shibayama, Katsuya Hisaichi, Hideaki Tada, Yoshikazu Takaoka, Chiaki Minamoto, Toshihiko Nishiyama, Kenji Sagawa, Hiromu Habashita, Masaaki Toda, Rena Nishizawa, Naoki Matsunaga, Daikichi Fukushima, and Hiroaki Mitsuya
- Subjects
Magnetic Resonance Spectroscopy ,Anti-HIV Agents ,Stereochemistry ,Metabolite ,Clinical Biochemistry ,Pharmaceutical Science ,CHO Cells ,Oxidative phosphorylation ,In Vitro Techniques ,Hydroxylation ,Biochemistry ,Chemical synthesis ,chemistry.chemical_compound ,Cricetulus ,Isomerism ,Cricetinae ,Drug Discovery ,Animals ,Combinatorial Chemistry Techniques ,Humans ,Chemokine CCL4 ,Molecular Biology ,Chromatography, High Pressure Liquid ,Active metabolite ,Chemokine CCL3 ,chemistry.chemical_classification ,Dipeptide ,Chemistry ,Organic Chemistry ,Antagonist ,Biological activity ,Macrophage Inflammatory Proteins ,Cyclic peptide ,Rats ,Drug Design ,CCR5 Receptor Antagonists ,Microsomes, Liver ,Molecular Medicine ,Indicators and Reagents ,Oxidation-Reduction ,Protein Binding - Abstract
Hydroxylated derivatives were designed and synthesized based on the information of oxidative metabolites. Compounds derived from β-substituted (2 R ,3 R )-2-amino-3-hydroxypropionic acid showed improved inhibitory activities against the binding of MIP-1α to human CCR5, compared with the non-hydroxylated derivatives and the other isomers.
- Published
- 2007
- Full Text
- View/download PDF